Background: Dexmedetomidine (DEX) effectively counteracts the hypertension induced by laryngoscopy and endotracheal intubation (ETI), minimizing the hemodynamic stress associated with these procedures. The study aimed to determine the optimal dose of dexmedetomidine for attenuating the hemodynamic pressor response to laryngoscopy and ETI. Methods: This randomized, prospective study, double-blinded study enrolled 60 patients between the ages of 18 and 60, including both sexes, with a type I or II physical state as defined by the American Society of Anesthesiology, having elective surgery while under general anesthesia while receiving ETI. Patients were randomized into two equal groups. Group A received 0.5 mcg/kg DEX, while Group B received 1 µg/kg DEX. DEX was diluted in 50 ml of normal saline and administered over 10 minutes as a single dose. Results: Group B had a much lower heart rate (HR) and cardiac output (CO) compared to group A at six measurements after induction and before laryngoscopy, and in ten readings following ETI (P<0.05). The systolic (SBP) and diastolic blood pressure (DBP) readings were considerably lower in group B compared to group A during three readings after induction and before laryngoscopy, as well as five readings following ETI (P<0.05). Stroke volume (SV) measurements were comparable between both groups. Conclusions: DEX 1 mcg/kg is superior to 0.5 mcg/kg in the hemodynamic pressor response to laryngoscopy and intubation attenuation as evidenced by lowering HR, SBP, DBP, and CO without a significant difference in SV.